Tivic Health Systems, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 0.6168 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 547.47K
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company’s pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Details
| Name | Valion Bio, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 52 |
| Founded | 2016 |
| Ipo Date | 2021-11-11 |
| Ceo | J. Zikria |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US9189422028 |
| Cusip | 918942202 |
| Cik | 1787740 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| J. Dean Zikria | Interim Chief Executive Officer and Director |
| Lisa G. Wolf | President, Chief Financial Officer and Chief Operating Officer |
Contact
| Address | 1305 E. Houston Street, Suite 311, Building 1, San Antonio, Texas 78205, United States |
| Phone | 888 276 6888 |
| Website | https://valionbio.com |